In a research report issued today, Wedbush analyst Zarak Khurshid reiterated an Outperform rating on shares of OvaScience Inc (NASDAQ:OVAS) with a $46 price …
Wedbush’s healthcare analyst Zarak Khurshid weighed in with a few insights on OvaScience Inc (NASDAQ:OVAS), after the company announced positive analysis of its AUGMENT fertility treatment, …
Wedbush analyst Zarak Khurshid maintained an Outperform rating on Illumina (NASDAQ:ILMN) with a $200 price target, following the release of GenomeWeb article entitled, “Undercover …
Wedbush analyst Zarak Khurshid maintained a Neutral rating on Exact Sciences Corp (NASDAQ:EXAS) with a price target of $19, which represents a potential …
In a research report issued today, Wedbush analyst Zarak Khurshid maintained a Neutral rating on Qiagen (NASDAQ:QGEN) with a price target of $20. …
In a research report issued yesterday, Wedbush analyst Zarak Khurshid maintained an Outperform rating on Cepheid (NASDAQ:CPHD) with a price target of $55. Khurshid …
In a research report published today, Wedbush analyst Zarak Khurshid maintained coverage on Cerus Corp. (NASDAQ:CERS) with an Outperform rating and a $6.
In a research note issued today, Wedbush analyst Zarak Khurshid reiterated coverage with a “Neutral” rating on Illumina Inc. (ILMN) and a price target of $155.
